Trial Profile
Phase III Clinical Trial, long term treatment with TO-204 - Subcutaneous immunotherapy in patients with HDM-sensitized allergic rhinitis and asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy injection ALK Abello (Primary)
- Indications Allergic asthma; Allergic rhinitis
- Focus Adverse reactions
- Sponsors Torii Pharmaceutical
- 09 Feb 2015 Status changed from active, no longer recruiting to completed, according to an ALK-Abello media release.
- 11 Nov 2014 New trial record